INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 41h ago
HOUSE PTR1h ago
SEC 13F1h ago
ROBINHOOD CHAIN1h ago
SEC FORM 4/Open-market saleVerified dataRule 10b5-1 plan

Murphy Andrew J sold REGN

Co-Chief Scientific Officer · REGENERON PHARMACEUTICALS, INC. · Common Stock

Side
SELL
Value
$26K
Shares
35
Price
$755.91
Executed
Oct 14, 2026
Disclosed
Oct 15, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Oct 14 executedOct 15, 2026 disclosed

REGN · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
5/ 100 · ROUTINE
Methodology →
  • Transaction type+6 / 20

    Open-market sale

  • Relative size+1 / 25

    $26K reported value · 0.1% of prior position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · REGN

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    34
    SL
    Sing George LDirector
    REGNREGENERON PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$194K
    200 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    12
    FR
    Fenimore Christopher R.EVP Finance CFO
    REGNREGENERON PHARMACEUTICALS, INC.
    Gift
    		G—
    15 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    26
    FR
    Fenimore Christopher R.EVP Finance CFO
    REGNREGENERON PHARMACEUTICALS, INC.
    Option exercise
    		M$2.29M
    6,000 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    9
    FR
    Fenimore Christopher R.EVP Finance CFO
    REGNREGENERON PHARMACEUTICALS, INC.
    Option exercise
    		M—
    6,000 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    44
    SL
    Sing George LDirector
    REGNREGENERON PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$1.47M
    1,522 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    44
    SL
    Sing George LDirector
    REGNREGENERON PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$4.18M
    4,338 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    26
    LJ
    Larosa Joseph JEVP General Counsel and Secret
    REGNREGENERON PHARMACEUTICALS, INC.
    Option exercise
    		M$4.69M
    12.3K sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    40
    SL
    Sing George LDirector
    REGNREGENERON PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$1.18M
    1,224 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    9
    LJ
    Larosa Joseph JEVP General Counsel and Secret
    REGNREGENERON PHARMACEUTICALS, INC.
    Option exercise
    		M—
    12.3K sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    26
    LJ
    Larosa Joseph JEVP General Counsel and Secret
    REGNREGENERON PHARMACEUTICALS, INC.
    Tax withholding
    		F$8.26M
    8,686 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    37
    SL
    Sing George LDirector
    REGNREGENERON PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$519K
    540 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    9
    SL
    Sing George LDirector
    REGNREGENERON PHARMACEUTICALS, INC.
    Option exercise
    		M—
    7,830 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    48
    SL
    Sing George LDirector
    REGNREGENERON PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$6.83M
    7,073 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    44
    SL
    Sing George LDirector
    REGNREGENERON PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$2.58M
    2,670 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    40
    SL
    Sing George LDirector
    REGNREGENERON PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$1.01M
    1,040 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    9
    SL
    Sing George LDirector
    REGNREGENERON PHARMACEUTICALS, INC.
    Option exercise
    		M—
    7,439 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    37
    LJ
    Larosa Joseph JEVP General Counsel and Secret
    REGNREGENERON PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$509K
    527 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    22
    SL
    Sing George LDirector
    REGNREGENERON PHARMACEUTICALS, INC.
    Option exercise
    		M$2.83M
    7,439 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    26
    SL
    Sing George LDirector
    REGNREGENERON PHARMACEUTICALS, INC.
    Option exercise
    		M$2.95M
    7,830 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    44
    SL
    Sing George LDirector
    REGNREGENERON PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$2.43M
    2,522 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001796226-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Oct 14, 2026
    Published
    Oct 15, 2026
    Ingested by INSIDER
    Nov 5, 02:11 UTC
    Last re-read
    Nov 5, 02:11 UTC

    Extracted facts

    Filer
    Murphy Andrew J
    Role
    Co-Chief Scientific Officer
    Transaction
    Open-market saleAs filed: “S”
    Asset
    REGENERON PHARMACEUTICALS, INC.
    Ticker
    REGN
    Shares
    35
    Price per share
    $755.91
    Value
    $26,457
    Execution date (reported)
    Oct 14, 2026
    Owned after transaction
    51.9K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    1

    Calculation

    Value = shares × reported price per share

    • Shares: 35
    • Price: $755.91

    = $26,457

    What this establishes

    Murphy Andrew J filed this Form 4 reporting a open-market sale of REGN on Oct 14, 2026. It became public on Oct 15, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Co-Chief Scientific Officer
    Murphy Andrew Jcik:0001796226
    Issuer
    REGENERON PHARMACEUTICALS, INC.cik:0000872589

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.